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ARTICLE
Genome-wide Association Analysis of Psoriatic
Arthritis and Cutaneous Psoriasis Reveals
Differences in Their Genetic Architecture
Philip E. Stuart,1,34 Rajan P. Nair,1,34 Lam C. Tsoi,1,2,3,34 Trilokraj Tejasvi,1,4 Sayantan Das,2
Hyun Min Kang,2 Eva Ellinghaus,5 Vinod Chandran,6,7 Kristina Callis-Duffin,8 Robert Ike,9
Yanming Li,2 Xiaoquan Wen,2 Charlotta Enerbäck,10 Johann E. Gudjonsson,1 Sulev Kõks,11,12
Külli Kingo,13 Tõnu Esko,14 Ulrich Mrowietz,15 Andre Reis,16 H. Erich Wichmann,17,18,19
Christian Gieger,20,21 Per Hoffmann,22,23 Markus M. Nöthen,22,23 Juliane Winkelmann,24,25
Manfred Kunz,26 Elvia G. Moreta,27 Philip J. Mease,28 Christopher T. Ritchlin,29 Anne M. Bowcock,30
Gerald G. Krueger,8 Henry W. Lim,31 Stephan Weidinger,15 Michael Weichenthal,15 John J. Voorhees,1
Proton Rahman,32 Peter K. Gregersen,33 Andre Franke,5 Dafna D. Gladman,6,7 Gonçalo R. Abecasis,2
and James T. Elder1,4,*
Psoriasis vulgaris (PsV) is a common inflammatory and hyperproliferative skin disease. Up to 30% of people with PsV eventually develop
psoriatic arthritis (PsA), an inflammatory musculoskeletal condition. To discern differences in genetic risk factors for PsA and cutaneousonly psoriasis (PsC), we carried out a genome-wide association study (GWAS) of 1,430 PsA case subjects and 1,417 unaffected control
subjects. Meta-analysis of this study with three other GWASs and two targeted genotyping studies, encompassing a total of 9,293 PsV
case subjects, 3,061 PsA case subjects, 3,110 PsC case subjects, and 13,670 unaffected control subjects of European descent, detected
10 regions associated with PsA and 11 with PsC at genome-wide (GW) significance. Several of these association signals (IFNLR1,
IFIH1, NFKBIA for PsA; TNFRSF9, LCE3C/B, TRAF3IP2, IL23A, NFKBIA for PsC) have not previously achieved GW significance. After replication, we also identified a PsV-associated SNP near CDKAL1 (rs4712528, odds ratio [OR] ¼ 1.16, p ¼ 8.4 3 1011). Among identified
psoriasis risk variants, three were more strongly associated with PsC than PsA (rs12189871 near HLA-C, p ¼ 5.0 3 1019; rs4908742
near TNFRSF9, p ¼ 0.00020; rs10888503 near LCE3A, p ¼ 0.0014), and two were more strongly associated with PsA than PsC
(rs12044149 near IL23R, p ¼ 0.00018; rs9321623 near TNFAIP3, p ¼ 0.00022). The PsA-specific variants were independent of previously
identified psoriasis variants near IL23R and TNFAIP3. We also found multiple independent susceptibility variants in the IL12B, NOS2,
and IFIH1 regions. These results provide insights into the pathogenetic similarities and differences between PsC and PsA.

Introduction
Psoriasis vulgaris (PsV [MIM: 177900]) is a chronic, immune-mediated disease of the skin characterized by
inflammation and epidermal hyperplasia, with a preva-

lence of 0.2%6.5%, depending upon the population of
origin.1 Approximately 15%30% of people with psoriasis
will eventually develop psoriatic arthritis (PsA [MIM:
607507]), an often debilitating musculoskeletal condition
that is usually seronegative for rheumatoid factor.2 PsV
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and PsA pose increased risk for cardiovascular, autoimmune, metabolic, and psychiatric conditions.3–6
Both PsV and PsA have a strong genetic component.
Based on twin and family studies in populations of European descent, estimates of heritability for PsV range from
50% to 90%,7–12 with recurrence rates in siblings (ls) and
first-degree relatives (l1) of 4–19.13–16 The genetic contribution to PsA appears even larger, with estimates of
80%–100% for heritability13,15 and of 30–49 for ls and
l1.13,15–17 A series of large-scale genome-wide association
studies (GWASs) and genome-wide (GW) meta-analyses
during the past decade have identified nearly 70 genetic
loci harboring PsV risk variants.18–32 In contrast, only three
small to modestly sized GWASs for PsA have been published,19,33,34 which, together with analyses of candidate
loci in larger samples and recently published Immunochip
array studies, have identified 13 regions associated with
PsA at GW significance (p % 5 3 108): near HLA-B
(MIM: 142830) and HLA-C (MIM: 143840) in the major
histocompatibility complex (MHC)19,21,33,35–45 and also
near IL12B (MIM: 161561),21,33,45 IL23R (MIM:
607562),45 IL23A (MIM: 605580),45 TNIP1 (MIM:
607714),21,45,46 TRAF3IP2 (MIM: 607043),25,33,40,45 CSF2
(MIM: 138960),45 FBXL19 (MIM: 609085),24 REL (MIM:
164910),34 RUNX3 (MIM: 600210),47 TYK2 (MIM:
176941),45 NOS2 (MIM: 163730),48 and PTPN22 (MIM:
600716).48
There are no published GWASs of cutaneous-only psoriasis (PsC), which we define as the presence of skin symptoms without PsA for at least 10 years. Candidate studies
of PsC have identified seven associated genetic regions
achieving GW significance: near MHC genes HLA-C,
HLA-B, CCHCR1 (MIM: 605310), and TNF (MIM:
191160),21,33,37,40,42,49–53 and also near IL12B,21 TNIP1,21
TNFAIP3 (MIM: 191163),21 IL23R,21 NOS2,24 and IL13
(MIM: 147683).21
It is reasonable to hypothesize that the observed differences in phenotype, prevalence, and heritability of PsA
and PsC stem at least in part from differences in their underlying genetic architecture. Differences in strength of association with PsC and PsA have been repeatedly observed
for the MHC, including a stronger association of HLA-C*06
with PsC42 and a stronger association of HLA-B*27 with
PsA,41 both differences reaching GW significance. There
is a paucity of well-powered studies formally comparing association for PsA versus PsC outside of the MHC region.
A scan of the literature finds only ten non-MHC regions
with at least a nominally significant (p < 0.05) difference
in the strength of association for these two subphenotypes
of psoriasis—near IL13,54–57 CSF2 (MIM: 601267),45
CCR2,58 IFNG (MIM: 147570),54 IL12B,21,46 ZNF816,46
IL23R,21 FBXL19,24 PTPN22,48 and the KIR gene cluster.59
To address the need for more powerful and comprehensive genetic studies of PsA and PsC, we first carried out a
large GWAS of PsA, involving 1,430 PsA case subjects and
1,417 unaffected control subjects. We then combined results of this PsA GWAS with five published studies of pso-

riasis association—three GWASs and two targeted studies,
comprising a discovery meta-analysis of 3,061 PsA case
subjects, 3,110 PsC case subjects, 9,293 PsV case subjects,
and 13,670 unaffected control subjects. For markers with
promising association signals in this discovery analysis, a
large partially overlapping sample of up to 13,857 individuals was genotyped, allowing both independent replication and validation of the quality of imputed genotypes
in the discovery sample. We used stepwise conditional
regression to discover additional PsA, PsC, and PsV risk variants that were independent of the primary index signal in
each region. We then devised a bootstrap procedure to
compare the relative strength of PsA and PsC associations
for all strongly associated primary and secondary variants
detected by the discovery and replication analyses, as
well as for most variants previously reported as differentially associated with PsA versus PsC. Finally, we investigated potential functional consequences of our findings.

Material and Methods
Samples
All PsV case subjects were diagnosed by a dermatologist; a large
subset of these individuals was also evaluated for PsA by a rheumatologist. Individuals affected with PsV for 10 or more years without
developing any signs of PsA were classified as PsC. For all studies,
each PsA and PsC case subject was also classified as a PsV case subject; the remaining PsV case subjects were PsA-negative individuals affected with psoriasis for less than 10 years or people for
whom a diagnosis of PsA was either unavailable or uncertain. Control subjects were 18 years of age or older and unaffected with PsV
or PsA. All participating individuals provided written informed
consent and were recruited according to the protocols approved
by the institutional review board of each institution.
For the PsA GWAS, 1,526 PsA case subjects and 1,508 unaffected control subjects were recruited by four collection centers—Michigan, Toronto, Newfoundland, and the National
Psoriasis Foundation. Samples for the other five studies in the discovery meta-analysis have been described previously. Three have
GW coverage, referred to here as the Collaborative Association
Study of Psoriasis (CASP),21 Kiel,25 and Genizon25,34 GWAS. The
other two are targeted genotyping studies: a deep follow-up study
of the CASP GWAS (CASP-DFU) designed to fine-map and replicate
association signals from this earlier GWAS60 and the Psoriasis Association Genetics Extension (PAGE) Immunochip-based
study.27 For these five published studies, case and control subjects
were recruited from local populations at each of 17 collection centers in 4 countries—the United States, Canada, Estonia, and Germany. The published PAGE Immunochip study was extended
with an additional 395 unaffected control subjects from the
United States and 568 PsA case subjects from the United States,
Canada, New Zealand, Australia, and 11 European countries. For
our replication/validation sample, we genotyped up to 13,857 individuals from six collection centers in the United States, Canada,
and Sweden (7,004 PsV case subjects, 2,554 PsA case subjects,
1,921 PsC case subjects, and 6,830 unaffected control subjects)
that partially overlapped the six studies in the discovery set. All
samples used in this study were of self-reported white European
ancestry.
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Genotyping and Quality Control
Samples for the PsA GWAS were genotyped with the Illumina
HumanOmni1-Quad BeadChip array (Illumina). Genotypes were
obtained for 1,020,596 autosomal SNPs. We removed SNPs with
a call rate < 95%, a HWE p in controls < 1 3 107, or a minor allele
frequency (MAF) < 0.01. Samples were removed if they had substantial non-European admixture, were duplicates or first- or
second-degree relatives of other samples, had a genotype call
rate < 98%, had outlier inbreeding coefficients (F < 0.0225 or
F > 0.0285), or were part of unresolvable sample swaps determined
by X chromosome genotypes.
Population outliers for the PsA GWAS were determined by principal components analysis (PCA), using SNPs passing the aforementioned quality-control filters that were further filtered to
exclude those with a MAF < 0.05 and those occurring in known
regions of psoriasis association. After linkage disequilibrium
(LD)-based pruning with version 1.7 of Plink61 to quasi-independence (maximum pairwise LD-r2 ¼ 0.20), 103,699 SNPs remained.
Genotypes for these SNPs were combined with HapMap2 genotypes for samples from the YRI, CEU, JPT, and CHB reference populations and subjected to PCA, and individuals lying farther than
1/10 of the distance between CEU and JPT/CHB/YRI when plotted
on the first two PCA axes were considered to have substantial nonEuropean admixture.
Array-based genotyping and subsequent quality control measures for the CASP GWAS, Kiel GWAS, Genizon GWAS, CASPDFU, and PAGE Immunochip were similar to those employed for
the PSA GWAS and have been described in detail previously.21,25,27,34,60 We used Plink61 and RelativeFinder62 to determine genetic relatedness of samples among all six discovery
studies, removing all but one of each cluster of duplicated samples
or first- or second-degree relatives, which ensured that meta-analysis was restricted to unrelated individuals.
We genotyped 25 markers to validate and replicate promising
signals from the discovery analysis. Genotyping was performed
by Taqman, Snapshot, or length polymorphisms assays (Life Technologies), or as part of a custom set on the Affymetrix Axiom Biobank Plus Array (Affymetrix), or both. We were unable to design
successful genotyping assays for three of the 25 markers (those
near CAMTA1 [MIM: 611501], NFKBIZ [MIM: 608004], and
LINC00701); for NFKBIZ we instead genotyped the second most
significantly associated marker (rs4683946) in the region. Subsequent validation analyses based on this genotyping found that 7
of the 23 follow-up markers had questionable imputation quality.
For one of these (rs8018217), we substituted a marker that was
more reliably imputed in the discovery analysis (rs3168891),
which is in near-perfect LD (r2 ¼ 0.985) with the primary signal,
and which also happened to be genotyped in the replication/validation set as part of the standard content of the exome array. Samples that failed to genotype for 3 or more of the 23 markers or that
were not of self-reported European ancestry were excluded from
downstream analysis. Samples were also excluded if they had
two or more discrepant genotypes among the 11 markers typed
twice by different methods. After sample filtering, genotyping success exceeded 95% and HWE test p values were >0.05 for all 23
markers.

Imputation
Version 1.0.16.b of MaCH63 was used to pre-phase haplotypes
based on genotype data for each of the six discovery studies.
Release 2012-05-29 of minimac64 was used to impute SNP and in-

del genotypes based on phased chromosomal haplotypes from the
379 individuals in the EUR subpopulation of release 3, phase 1 of
the 1000 Genomes Project.65 The following criteria were used to
flag markers with poor imputation despite passing our predicted
imputation quality threshold (r2 R 0.3): (1) a substantially
(ratio > 1.10 or < 0.91) and significantly (adjusted p < 0.05)
different MAF for imputed and experimental genotypes, (2) empirical imputation quality substantially (R0.1 r2 units) worse than
predicted, and (3) strength of association substantially (ratio of
log(OR) values > 1.1 or < 0.91) and significantly (p < 0.05)
different when comparing association results from meta-analysis
of imputed and assayed genotypes.

Association Tests
We used logistic regression to test for association of variants with
the binary case-control phenotype. Variant genotypes were coded
as imputed allele dosages. To control for population stratification
in array-based studies, we used coordinates from the top ten dimensions of PCA or multidimensional scaling analysis as covariates in the regression model for each individual study. Geographic
cohort covariates were also included for the PsA GWAS, CASP
GWAS, and PAGE Immunochip studies, as well as when analyzing
the replication and validation markers. To test for associations that
were independent of the primary signal in a region, we utilized
stepwise forward logistic regression. The regression model in this
case included imputed allele dosages of the most significantly
associated variant as an additional covariate. Dosages of the
most significantly associated variant in the region when conditioning upon the primary signal were then included as a new
covariate in the next round of stepwise analysis, providing its significance exceeded the threshold set to correct for multiple testing
(p % 1 3 106, based on the number of LD-independent tested
variants within all analyzed regions and phenotype comparisons
combined). To test for epistasis between pairs of variants, imputed
allele dosages of the two tested variants and a multiplicative
dosage interaction term were included in the logistic regression
model along with cohort and PCA covariates.
Inverse variance-weighted fixed-effects meta-analysis was used
to combine association results across datasets. For the initial sixstudy discovery analysis, all variants for which at least one study
had good imputation quality (r2 R 0.3)63 were tested; no minimum MAF criterion was imposed. For meta-analysis of stepwise
regression results and generation of association meta-p-values
needed for construction of 95% Bayesian credible sets, the analyses for a region were restricted to those discovery studies with
good coverage in the region, and only those markers well imputed
in all included studies were tested. Heterogeneity of ORs across
studies was tested with Cochran’s Q test.
We utilized QQ plots and the genomic inflation factor (lGC) to
test for residual effects of population stratification not fully
controlled for by the inclusion of PCA and cohort covariates in
the regression model. All variants in regions of known association
at the time of the analysis27 were excluded, and variants were also
LD-pruned with version 1.7 of Plink61 (window size ¼ 50, step ¼ 5,
pairwise r2 threshold ¼ 0.2).
A posteriori power of detecting significant (a ¼ 0.05) association
for markers in the replication sample was determined with the
Genetic Power Calculator.66 For power analysis, estimates of ORs
and their 95% confidence intervals were based on results from
the discovery meta-analysis that had been adjusted for ascertainment bias (winner’s curse).67
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Linkage Disequilibrium
We computed D0 and r2 measures of LD for pairs of variants using
genotypes of 379 individuals of European ancestry (EUR subpopulation) in release 3 of phase 1 of the 1000 Genomes Project.65
Blocks of LD in regions of association were delineated by
the D0 confidence interval method68 based on all SNPs with
MAF R 0.05 in the same EUR subpopulation. Version 1.7 of Plink
was used for all LD calculations.61

Phenotypic Variance Explained
For the non-MHC risk variants detected by this study, which are all
biallelic, we used a liability threshold model to compute separately
for each variant the percent variance of liability for disease explained.69 Relative risk was approximated by the log-additive
OR, frequency of the risk allele in the underlying population
was estimated as a weighted average of its frequency in PsV case
subjects and unaffected control subjects (weights ¼ 0.02 and
0.98, respectively) of our combined discovery set, and population
prevalences for PsV, PsA, and PsC were assumed to be 0.02, 0.003,
and 0.017 based on published data.1 For regions with multiple risk
variants, we adjusted values for any interdependencies due to LD
by first computing the variance explained by the correlated SNPs
as a group69 and then partitioning this total explained variance
into non-overlapping variances for each SNP by the method of
Pratt.70 For the MHC, which contains several correlated multiallelic polymorphisms that influence risk for psoriasis, we applied
a multiallelic extension of the biallelic method69 to ORs derived
from a full regression model containing all MHC risk variants
and their multiple alleles that were identified by stepwise regression analysis of our six discovery studies.44

Comparison of Effect Sizes for PsA and PsC
Associations
We used both parametric and bootstrap methods to compare effect
sizes from meta-analysis of PsA case versus control subjects and of
PsC case versus control subjects. With the exception of the PsA
GWAS, the unaffected control subjects are shared by all discovery
studies in these two meta-analyses, so the two meta-ORs are
dependent random variables. A test statistic for the difference in
two dependent ORs can be formulated as
ðbPsA  bPsC Þ2
pﬃﬃﬃﬃﬃﬃﬃﬃﬃpﬃﬃﬃﬃﬃﬃﬃﬃﬃ;
VPsA þ VPsC  2rPsA;PsC VPsA VPsC
where bPsA and bPsC are the log ORs for PsA-affected versus control
individuals and PsC-affected versus control individuals, VPsA and
VPsC are the variances of these log ORs, and rPsA,PsC is the correlation of the two log ORs. Under the null hypothesis of no difference
in the two effects, this test statistic follows a c2 distribution with 1
degree of freedom. Although the log ORs and their variances for
the six discovery studies can be estimated by fixed-effects metaanalysis, there is no analytic approximation for the correlation
of the ORs. As expected, simulations show that the correlation is
nearly always positive but that its value varies substantially, especially in response to the relative and absolute magnitudes of the
observed effect sizes. Setting the last term in the denominator of
the test statistic to zero, equivalent to assuming independence of
the two ORs, affords a rapid albeit conservative parametric test.
As an alternative, we devised a bootstrap procedure. For each of
the six discovery studies, we separately sampled with replacement
PsA case subjects, PsC case subjects, and unaffected control subjects, maintaining the same sample sizes as in the original studies.

Association tests for PsA case versus control subjects and PsC case
versus control subjects were then run for each individual study,
followed by fixed-effects meta-analysis for each of the two phenotype comparisons, using the same logistic regression models
applied to the observed data. Sampling and testing were repeated
50,000 times. A c2 test statistic was computed by dividing the
square of the difference in the two observed log meta-ORs by
the variance of their difference, where the latter is computed
from the 50,000 bootstrap estimates of the difference. This standard bootstrap approach71 yielded very similar p values to other
bootstrap methods (percentile, bias-corrected). To validate the
bootstrap approach, we inspected all final and intermediate bootstrapped estimates for 100,000 iterations of 52 independently
associated markers. For all markers, the bootstrapped distribution
for the difference in log ORs was normal (Lilliefor’s test p > 0.05)
and bias was negligible (mean and median bias ¼ 0.0001 and
0.0000, respectively). Furthermore, for all markers and each
phenotype comparison, bootstrapped and parametric association
results for the individual studies and the meta-analysis were very
similar.

Bayesian Credible Sets
Using a Bayesian approach, for selected association signals we
identified the credible set of markers that were 95% likely, based
on posterior probability, to contain the causal disease-associated
variant. Although the concept was based on the approach of Maller et al.,72 our method used a Bayes factor derived from more
recent work73 that explicitly considers meta-analysis. Input for a
signal consisted of meta-ORs and their standard errors for all
markers within 500 kb of the most significantly associated variant
in the six-study discovery analysis.

Analysis of RNA Expression
We used the Wilcoxon rank-sum test to test for differences in
RNA expression levels, derived by RNA-seq, between 92 punch
biopsies of lesional skin from psoriatic individuals versus 82
biopsies of normal skin from unaffected control subjects, as
described previously.74 To declare a gene as differentially
expressed, we required a 2-fold or greater difference in median
RPKM-normalized transcript levels, with a rank-sum test
p < 106 (corresponding to a family-wise error rate < 0.025 for
all genes with detectable expression in at least half of the lesional
or normal skin biopsies).
For analysis of possible eQTL variants, RNA levels were determined for all gene models in Ensembl v.74 for the same 92 lesional
and 82 normal skin biopsies, using version 1.3.3 of Tophat75 for
alignment and version 2.1.1 of Cufflink76 for ab initio transcript
assembly, as described previously.77 All 92 lesional samples and
all but two of the 82 normal samples were genotyped on the Affymetrix Axiom Biobank Plus Array, which contains a GWAS
backbone panel of 260,000 SNPs in addition to exome and custom
content. After quality control, high-quality genotypes for 586,178
SNPs were available for GW imputation using all populations of
release 1 of phase 3 of the 1000 Genomes Project. All Cufflinknormalized RNA values < 0.1 were treated as zero. Only those
genes with RNA expression > 0 in at least 20% of the normal or
20% of the lesional samples were analyzed. Before analysis, we first
applied a square-root transformation for variance stabilization,
then standardized separately within lesional and normal groups
to a mean of zero and standard deviation of one. Merlin-offline,
distributed as part of version 1.1.2 of Merlin,78 was used to test
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for significant correlation of transcript levels with imputed allele
dosages of variants; inverse normalization was applied to the
expression levels, and the top two principal components and an
indicator variable for lesional/normal skin were included as covariates in the association model.
The RNA expression data used in these analyses are available at
NCBI’s Gene Expression Omnibus (GEO accession number
GSE63979). Details of the generation of these data by RNA-seq,
QC metrics, and validation of normalized expression values are
presented elsewhere.74,77

Annotation Analysis
For associated variants, the UCSC Table Browser79 was used to
extract PhastCons, PhyloP, and Gerpþþ conservation scores, as
well as location within CpG islands, from hg19 reference assembly
tracks phastCons100way, phyloP100wayAll, allHg19RS_BW, and
cpgIslandExt, respectively. Version 2014-11-12 of ANNOVAR80
was used to determine positions of variants relative to RefSeq
genes. Version 3 of HaploReg81 was used to determine how
many cell types among the ENCODE and Roadmap reference epigenomes have promoter histone marks, enhancer histone marks,
or DNase I hypersensitivite sites overlapping a variant, as well as
ChIP-seq evidence of transcription factors that bind to the interval
containing the variant, and which transcription factor binding
sites motifs are changed by a variant. Version 1.1 of RegulomeDB82 was used to obtain scores of how likely it is that a variant
has regulatory function, and version 1.2 of CADD83 provided
scores of variant deleteriousness. The overlap of associated variants with chromatin states of 33 cell types relevant to psoriasis,
which were derived from a 15-state segmentation model based
on five chromatin marks, was based on results of analyses generated by the Roadmap Epigenomics Project.84

Results
PsA GWAS
Application of quality control filters to the PsA GWAS
yielded high-quality genotypes at 791,217 SNPs for 1,430
PsA case subjects and 1,417 control subjects. Demographic
details of the post-filtering sample collection are shown in
Table S1. After imputation, genotypes for 11,532,644 SNPs
and 918,976 indels were available for downstream
analysis. QQ plots and genomic inflation factors
(1.0131.025) for four different MAF bins of the imputed
variants indicated good control of population stratification
(Figure S1).
Five regions in the PsA GWAS were associated at GW significance (Figure S2, Table S2). These were all known risk
regions for PsA, and the strongest signals were near
HLA-B (rs36058333, OR ¼ 2.13, p ¼ 1.3 3 1029), IL12B
(rs918520, OR ¼ 1.50, p ¼ 9.3 3 1010), TRAF3IP2
(rs33980500, OR ¼ 1.74, p ¼ 4.2 3 109), TNIP1
(rs8177833, OR ¼ 1.75, p ¼ 3.7 3 108), and TYK2
(rs35251378, OR ¼ 1.41, p ¼ 3.5 3 108). Five additional
regions surpassed a suggestive threshold of significance
(p ¼ 1 3 106), four of which (near TNS1 [MIM: 600076],
ATP10D, PTPRN2 [MIM: 601698], CTNNA3 [MIM:
607667]) have no previously reported risk variants for
PsV or PsA.

Meta-analysis of Six Discovery Studies
To increase power and extend our analysis to include PsC
case subjects, we combined the results of the PsA GWAS
with those of five published genetic studies of psoriasis
in people of European descent. Three of these studies
have GW coverage; the other two use targeted genotyping
arrays. As shown in Table 1, the four GWASs combined provided a discovery set of 4,007 PsV, 1,946 PsA, and 1,363
PsC case subjects as well as 4,934 unaffected control subjects. The two targeted studies provided an additional
5,286 PsV, 1,115 PsA, and 1,747 PsC case subjects and
8,736 control subjects for a subset of the genome. The
five additional datasets were imputed to the same reference
panel as the PsA GWAS. Fixed-effects meta-analysis was
used to test for association of the six discovery studies combined. The four phenotype comparisons tested were PsV
case versus unaffected control subjects, PsA case versus unaffected control subjects, PsC case versus unaffected control subjects, and PsA case versus PsC case subjects. The
PsA GWAS was excluded from the latter two meta-analyses
because it did not include any PsC case subjects. For each
of the four phenotype comparisons, QQ plots of p values
from the meta-analyses indicated good control of population stratification (Figure S3), as did genomic inflation
factors for the six individual studies as well as for the
meta-analyses (Table S3).
The Manhattan plots in Figure 1 label all regions with
GW significant association detected by the four meta-analyses (see Tables S4–S7 for detailed results). Figure 1A
shows 26 GW significant regions for the test of PsV case
versus unaffected control subjects; all harbor known PsV
susceptibility variants, including two near CAMK2G
(MIM: 602123) and NFKBIZ that were recently published
as psoriasis associated32 based on a sample that has a large
overlap with the discovery sample of this study. Figure 1B
shows ten regions with GW significant association for
PsA. Seven of these were previously known (near IL23R,
REL, TNIP1, IL12B, HLA-C, TRAF3IP2, and TYK2) and
the other three were newly established at GW significance—IFNLR1 ([MIM: 607404] rs7540214, OR ¼ 1.40,
p ¼ 1.6 3 108), IFIH1 ([MIM: 606951] rs1990760,
OR ¼ 1.22, p ¼ 1.8 3 108), and NFKBIA ([MIM:
164008] rs12883343, OR ¼ 1.22, p ¼ 2.6 3 109). Twelve
regions with GW significant association were identified by
meta-analysis of PsC cases (Figure 1C), including six
known PsC signals (near IL13, TNIP1, IL12B, HLA-C,
TNFAIP3, and NOS2) and a candidate locus near RGS6
([MIM: 603894] rs12895275, OR ¼ 1.65, p ¼ 2.0 3 108).
In addition, five known PsV signals were newly established as associated with PsC at GW significance—TNFRSF9 ([MIM: 602250] rs4908742, OR ¼ 1.22,
p ¼ 2.2 3 108), LCE3C/B ([MIM: 612615, 612614]
rs10888503, OR ¼ 1.25, p ¼ 1.8 3 1011), TRAF3IP2
(rs9481169, OR ¼ 1.39, p ¼ 5.7 3 1011), IL23A
(rs11575231, OR ¼ 1.48, p ¼ 7.9 3 109), and NFKBIA
(rs61251127, OR ¼ 1.25, p ¼ 1.3 3 108). Meta-analysis
of PsA case versus PsC case subjects identified only two
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Table 1.

Characteristics of the Six Studies in the Discovery Meta-analysis
No. Imputed Variantsb

No. Individuals
No. Genotyped SNPsa

SNPs

Indels

2,847

791,217

11,532,644

918,976

2,741

438,609

10,708,247

865,325

1,135

1,599

504,637

10,730,120

872,971

399

993

1,754

489,501

10,525,123

863,572

133

575

1,141

2,704

7,592

207,911

18,001

3,723

982

1,172

7,595

11,318

168,360

1,654,147

141,025

9,293

3,061

3,110

13,670

22,963

–

Study

PsV

PsA

PsA GWAS

1,430

1,430

0

1,417

CASP GWAS

1,352

344

695

1,389

Kiel GWAS

464

33

269

Genizon GWAS

761

139

CASP-DFU

1,563

PAGE Immunochip
All

PsC

Controls

Total

–

–

Abbreviations are as follows: PsV, psoriasis vulgaris; PsA, psoriatic arthritis; PsC, cutaneous psoriasis.
a
After applying all quality control measures.
b
Restricted to variants with minimum acceptable imputation quality (MaCH-r2 R 0.3).

GW significant peaks (Figure 1D). One is a well-known
signal near HLA-C and HLA-B (rs1050414, OR ¼ 1.53,
p ¼ 7.4 3 1011). The second is a previously unreported
association near LOC100505817 on chromosome 18
(rs4891505, OR ¼ 1.63, p ¼ 6.7 3 109), which is an uncharacterized long non-coding RNA.
The discovery meta-analysis found nominal (p % 0.05)
association at all previously reported GW-significant signals for PsV, PsA, and PsC in populations of European
ancestry, and association at p % 1 3 105 for most of
them (76%, 77%, and 100%, respectively) (Table S8). In
contrast, just 23% of the PsV-associated regions detected
only in Chinese populations reached even nominal association in our study.
Validation and Replication of Candidate Signals
The discovery analyses uncovered 25 regions with no published psoriasis variants at the time of analysis that were at
least suggestively associated (p < 1 3 106) with PsV, PsA,
or PsC (Tables S4–S7). In order to replicate these promising
association signals in an independent sample, and also to
validate their imputed dosages in the discovery sample,
we genotyped up to 13,857 individuals of European
descent that partially overlapped the discovery set. Depending upon the phenotype comparison being tested,
the imputation quality of a marker across the six discovery
studies, and the method of assay, this yielded a set of
2,6158,415 retyped individuals for validation of imputation quality and of 2,6027,779 newly typed individuals
for independent replication.
Samples from four of the discovery studies (CASP GWAS,
PsA GWAS, CASP-DFU, and PAGE Immunochip) were retyped for the 23 successfully assayed replication markers.
We assessed reliability of imputation (Figures S4–S6; see
Material and Methods for more details) and found that 7
of the 23 replication markers (near BHLHE40 [MIM:
604256], USP49, JAK2 [MIM: 147796], ZNF462, MBIP
[MIM: 609431], RGS6, and APOBEC3G [MIM: 607113])
might have unreliable imputation quality in at least one
study of the discovery analysis (Table S9).

After exclusion of poorly imputed markers for which we
could find no well-imputed substitute, the newly typed
samples provided an independent replication of 17 association signals. Association statistics for these markers for
the discovery set, the replication set, and the two sets
combined are given in Table 2 (see Table S10 for full results for all 25 suggestively associated signals). Only two
of the markers (rs4712528 near CDKAL1 [MIM: 611259]
and rs2675669 near CAMK2G) were significantly associated in the replication set, which pushed the evidence
of their association with PsV to GW significance in the
combined analysis (OR ¼ 1.16, p ¼ 8.4 3 1011 for
CDKAL1; OR ¼ 1.13, p ¼ 3.9 3 1011 for CAMK2G).
Neither of these SNPs showed significant heterogeneity
of association across studies in the combined analysis (Cochran’s Q test p ¼ 0.54 and 0.42, respectively). The
CAMK2G region has recently been shown to be associated
with psoriasis based on a sample that has substantial overlap with the one used in this study,32 but to our knowledge GW-significant psoriasis association for a CDKAL1
variant has not been previously described. The association
peak for CDKAL1 lies fully within the gene, near its 50 end
(Figure S7). Two SNPs that were associated at GW significance in the discovery stage (near NFKBIZ and
LOC100505817) were no longer associated at this level
in the combined analysis.
Conditional Association Analysis to Identify
Secondary Susceptibility Variants
We next investigated whether we could detect additional
susceptibility variants independent of the best signal
in any of the regions attaining suggestive significance
(p ¼ 1 3 106) in our discovery analysis. To this end, for
each of the six discovery studies, we utilized stepwise forward logistic regression. We excluded the MHC region
from our analysis, because we have recently published a
fine-mapping analysis of this region for PsV, PsA, and PsC
associations based on the same six discovery sets of this
study.44 For each region, all markers within 500 kb of the
primary signal were candidates for conditional analysis.
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Figure 1. Manhattan Plots of Association Results for Meta-analysis of Six Discovery Studies
Each circle represents the log10(p) of the imputed variants, including SNPs and indels. Thresholds of suggestive (p ¼ 1 3 106) and GW
(p ¼ 5 3 108) significance are delineated with blue and red lines, respectively. All chromosomal regions achieving GW significance are
highlighted in green and labeled with their leading candidate susceptibility gene. Font color of the candidate genes indicates published
GW significant associations with psoriasis and its cutaneous and joint subphenotypes: purple indicates known PsA, PsC, and PsV association, red indicates known PsA and PsV association, cyan indicates known PsC and PsV association, black indicates known PsV association, and green indicates possible new psoriasis association. We tested association for four binary phenotypes: PsV case versus control
subjects (A), PsA case versus control subjects (B), PsC case versus control subjects (C), and PsA case versus PsC case subjects (D).

The results of meta-analysis of qualifying studies are
shown in Table S11 and Figures S8–S13. Variants independent of the primary signal were detected in four susceptibility regions, containing candidate genes IL23R, IL12B,
NOS2, and IFIH1. Multiple secondary signals upstream of
IL12B were associated with PsV, PsA, and PsC, yielding,
respectively, a total of five, four, and three independent
variants in this region for these three phenotypes. Two
PsV-associated conditional signals were observed for
IL23R, the first near the 50 end and the second near the
30 end of the gene. A single secondary signal near NOS2
was associated with PsV, and another secondary signal upstream of IFIH1 was associated with PsA. A comparison of
unconditional and full model association results for these
four regions reveals that the identified signals within a region are not fully independent of each other. Because of
both positive and negative LD among the variants, several
show either much weaker or much stronger association in
the full model than when tested in isolation.
Epistasis of Psoriasis Susceptibility Variants
We tested for statistical interaction among pairwise combinations of all known or newly established primary plus all
secondary risk variants reaching adequate statistical signif-

icance in the discovery analysis (p % 1 3 107 for primary
signals; p % 1 3 106 for secondary signals). For PsV,
positive epistasis was observed between the risk alleles of
the primary MHC variant (rs12189871) and the ERAP1
(MIM: 606832) variant (rs30377) (interaction OR ¼ 1.14;
p ¼ 4.6 3 106) and the risk alleles of the MHC
variant and the LCE variant (rs10888503) (OR ¼ 1.26;
p ¼ 6.9 3 1010), confirming previous reports of epistasis
for these two pairs of loci.23,27,85,86 No pairs of PsA or
PsC risk variants showed significant interaction after
correction for multiple testing.
Comparison of Strength of Association with PsA
and PsC
Genetic association with PsA and PsC case subjects was
directly compared in the discovery meta-analysis
(Figure 1D). This analysis necessarily omitted nearly half
of the PsA case subjects because they were from the PsA
GWAS, which had no PsC case subjects. We thus turned
to a conservative parametric test of the ratio of the ORs
from the meta-analyses of PsA case versus control subjects
and PsC case versus control subjects. As shown in
Figure S14, the increase in power due to inclusion of all
PsA case subjects yielded a peak MHC signal (rs2523615,
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Table 2.

Selected Results for Previously Unreported Regions of Psoriasis Association

Marker
rs13396545

Chr
2

hg19
Positiona
215,672,833

Alleles
(Risk/Nonrisk)
A/G

Nearby Gene
BARD1

Phenotype
Comparisonb
PsA-PsC

Discovery (6-Study Meta)

Replication

No. Cases/
Controls

No. Cases/
Controls

OR

p

1,663/1,101

0.93

0.4

799/1,438

1.08

1,949/2,440

516/1,363

OR
1.59

p
9 3 10

7
7

rs4685408

3

16,996,035

G/A

PLCL2

PsV-ctl

9,293/13,670

1.12

4 3 10

rs4683946

3

101,615,826

G/T

NFKBIZ

PsV-ctl

7,730/12,529

1.19

1 3 108
7

Combined (Meta)
OR

p

2,179/2,464

1.17

0.01

0.2

10,092/15,108

1.12

2 3 107

1.05

0.4

9,679/14,969

1.16

7 3 108

162/2,440

1.21

0.2

3,090/14,969

1.27

9 3 108

2,839/9,723

1.91

3 3 105

2,770/8,988

1.63

0.02

11,516/16,855

1.16

8 3 1011

rs4683946

3

101,615,826

G/T

NFKBIZ

PsA-ctl

2,928/12,529

1.27

2 3 10

rs72622783

4

32,577,723

T/C

—

PsA-ctl

1,946/4,934

2.78

3 3 107

893/4,789

1.08

0.7

rs113633694

4

68,949,589

T/C

TMPRSS11F

PsA-ctl

1,602/3,545

7.13

5 3 107

1,168/5,443

0.88

0.6

7

No. Cases/
Controls

5
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2,223/3,185

1.22

6 3 10

1 3 107

1,596/1,140

1.04

0.5

2,750/2,980

1.23

4 3 105

2 3 107

343/2,996

0.99

1.0

2,289/7,930

1.45

3 3 106

342/2,889

0.91

0.6

3,452/15,142

1.33

2 3 106

2,819/9,678

1.25

1 3 106

11,516/16,861

1.13

4 3 1011

rs4712528

6

20,678,430

C/G

CDKAL1

PsV-ctl

9,293/13,670

1.14

2 3 10

rs4725242

7

1,629,781

C/T

PSMG3

PsA-PsC

1,154/1,840

1.46

rs56677333

8

6,750,801

C/A

DEFB1

PsA-ctl

1,946/4,934

1.59

8

rs7922314

10

64,538,279

C/T

ADO

PsC-ctl

3,110/12,253

1.42

9 3 10

rs12356475

10

67,761,720

C/T

CTNNA3

PsA-ctl

1,946/4,934

1.38

8 3 108

873/4,744

1.08

0.3

rs2675669

10

75,653,872

T/C

CAMK2G

PsV-ctl

9,293/13,670

1.13

2 3 108

2,223/3,191

1.16

3 3 104

rs149014202

13

29,436,518

T/C

SLC46A3

PsA-ctl

297

2 3 107

1,768/4,936

1.84

0.1

1,801/6,071

3.49

0.001

33/1,135

5

rs3168891

14

36,789,729

T/G

MBIP

PsV-ctl

4,007/4,934

1.35

1 3 10

3,789/3,990

0.93

0.4

7,796/8,924

1.14

0.009

rs35144987

14

62,725,664

T/–

LINC00643

PsC-ctl

2,535/11,112

1.24

8 3 107

1,222/5,648

1.02

0.7

3,757/16,760

1.15

4 3 105

rs17052344

17

21,717,543

A/G

FAM27L

PsC-ctl

2,535/11,112

1.24

1 3 107

1,220/5,625

1.08

0.2

3,755/16,737

1.18

4 3 107

2,101/1,221

1.04

0.7

3,599/3,756

1.30

1 3 105

3,234/3,804

1.02

0.6

10,964/16,333

1.09

2 3 105

9

rs4891505

18

71007958

A/C

LOC100505817

PsA-PsC

1,498/2,535

1.63

7 3 10

rs6088273

20

30045393

A/G

DEFB123

PsV-ctl

7,730/12,529

1.14

9 3 107

Regions in table had no published reports of GW significant association with PsV, PsA, or PsC at time of analysis (February 2014). Abbreviations are as follows: chr, chromosome; PsV, psoriasis vulgaris; PsA, psoriatic arthritis;
PsC, cutaneous psoriasis; ctl, unaffected control; OR, odds ratio.
a
For insertions or deletions of the reference sequence, position of first base before the insertion point or of first base of the deleted sequence is shown, respectively.
b
Binary phenotype tested for association: PsA-ctl, PsA case versus unaffected control subjects; PsC-ctl, PsA case versus unaffected control subjects; PsV-ctl, PsV case versus unaffected control subjects; PsA-PsC, PsA case versus
PsC case subjects; PsA-PsCþctl, PsA case versus combination of PsC case and unaffected control subjects.

OR ¼ 1.91, p ¼ 9.9 3 1028) 17 orders of magnitude more
significant than the best MHC signal from the PsA versus
PsC meta-analysis. The signal in LOC100505817 on chromosome 18, which was GW significant in the meta-analysis of PsA versus PsC case subjects but failed independent
replication, does not reach suggestive significance in this
analysis.
We devised a bootstrap procedure to compare ORs from
the PsA versus control and PsC versus control subject metaanalyses. Although the bootstrap approach remedies the
modestly conservative nature of the parametric test
(Figure S15), it is too computationally demanding for
GW analysis. We instead first applied the bootstrap test
to the four non-MHC regions with p < 1 3 105 from
GW analysis using the parametric test. The significance
of association increased for the best variant in each
of the four regions, but still failed to reach suggestive
(p ¼ 1 3 106) significance.
We then applied the bootstrap test to all known and
newly established psoriasis signals with strong evidence
of association (p % 1 3 107) in the discovery analysis,
as well as to all secondary signals uncovered in the conditional analysis. The most significantly associated variant
for each of the four phenotype comparisons that met the
aforementioned criteria was tested. Nine variants,
comprising five LD-independent groups, had an FDRadjusted p < 0.05 for a test of the null hypothesis of equal
strength of association with PsA and PsC (Table 3; Table
S12 has results for all 59 tested variants). Three of these
groups were variants whose PsV risk allele was more
strongly associated with PsC than PsA—rs4908742 near
TNFRSF9 (OR ¼ 1.19, p ¼ 0.00020; Figures 2A–2C),
rs10888503 near LCE3C/B (OR ¼ 1.15, p ¼ 0.0014; Figures
2D–2F), and four SNPs (rs1050414, rs12189871,
rs13214872, and rs13210419) near HLA-C (OR ¼
1.341.80, p ¼ 5.5 3 1091.7 3 1021). The other two
groups were variants whose PsV risk allele was more
strongly associated with PsA than PsC—two SNPs
(rs12044149 and rs4655683) upstream of IL23R (OR ¼
1.20 and 1.14, p ¼ 0.00018 and 0.0075, respectively) and
SNP rs9321623 (OR ¼ 1.17, p ¼ 0.00022), which lies 230
kb upstream of TNFAIP3.
The PsA-specific signals upstream of IL23R and TNFAIP3
are of particular interest, as they are independent of all published PsV associations. Figures 3A–3C clearly show two
LD-independent peaks of association for IL23R—the PsAspecific peak near the 50 end of the gene, and a peak associated with both PsA and PsC near the 30 end of the
gene. Similarly, Figures 3D–3F illustrate two independent
peaks of association for the TNFAIP3 region—the PsA-specific peak well upstream of the gene, and a peak within
TNFAIP3 that is associated with both subphenotypes. The
published PsV associations for each of these two regions
are in LD with the second but not first peak of association.
Finally, we attempted to confirm previous reports of nonMHC variants exhibiting significantly different association
with PsA versus PsC. As shown in Table S13, we applied the

bootstrap test to 10 of 12 such variants (the other two, a
copy-number variant affecting KIR2DS2 [MIM: 604953]
and a microsatellite within IFNG, were not in our discovery
set). We could confirm only two of the previous findings, for
rs2201841 near IL23R (OR ¼ 1.10, p ¼ 0.035) and for
rs2476601 in PTPN22 (OR ¼ 1.16, p ¼ 0.041). The original
report for rs2201841 was based on a subset of the discovery samples in the current study; this SNP is not in
LD with either of the PsA-specific variants uncovered here
(r2 < 0.1), but is in moderate LD (r2 ¼ 0.62) with
rs116238258, the second conditional PsV signal we detected in the IL23R region. Variants mapping near CCR2,
CSF2, IL13, IL12B, FBXL19, and ZNF816 showed no evidence of differential association with PsA versus PsC.
Non-confirmation of the PsA specificity of the CSF2 association was unexpected given the robustness of the original
report.45 Although we were able to confirm the existence
of a PsA signal near CSF2 that is independent of association
with nearby IL13, we also detected comparable IL13-independent association with PsC (Figure S16). Our inability
to confirm putative PsA-specific signals at IL13 itself (Table
S12, Figure S16) is also noteworthy given the multiple positive reports for three different IL13 SNPs.54–57
Disease Liability for Regions with Multiple Risk
Variants
Table S14 lists, for each independent non-MHC risk variant
for PsV, PsA, or PsC identified by this study, an LD-adjusted
percent of variance in disease liability explained. The total
proportion of disease liability explained by all non-MHC
variants combined summed to 7.80%, 4.49%, and 4.91%
for PsV, PsA, and PsC, respectively. These figures increased
to 14.39%, 9.22%, and 12.10% when the contribution of
the MHC region44 was also considered.
Table S14 includes variants in 29 distinct genomic
regions. Sixteen of these regions contained only one independent signal, eight regions had two signals that were in
substantial pairwise LD (r2 ¼ 0.461.00), and five regions
(IL12B, IL23R, NOS2, IFIH1, and TNFAIP3) had two or
more signals, at least one pair of which were in low pairwise
LD (r2 < 0.3). Figure 4 displays disease liability plots for the
five regions with at least two independent signals. Plotting
disease liabilities allowed a more meaningful comparison of
relative risk for multiple variants in a region than did association statistics such as p values or ORs. These plots also allowed unified display for primary and conditional signals of
different disease phenotypes, as well as visual representation of LD and spatial relationships of the risk variants
with each other and with candidate genes. Spatially, the
risk variants in Figure 4 aggregated into one (NOS2), two
(IL23R, TNFAIP3, IFIH1), or four (IL12B) distinct clusters.
The number of LD-independent clusters per region varied
from two to four based on the D0 measure and from two to
five based on the r2 measure. Most of the 19 plotted variants
fell outside of the leading candidate gene for the region, but
six were intronic (IL23R, TNFAIP3, NOS2, and IFIH1) and
two exonic (IFIH1).
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Table 3.

Selected Results for Comparative Strength of Association of PsA versus PsC for Established Psoriasis Variants
Index Marker for:c

Candidate
Gene

Rnda

Marker

Chr

Position
(hg19)b

TNFRSF9

0

rs4908742

1

8,245,030

IL23R

0

rs12044149

1

67,600,686

IL23R

1

rs4655683

1

67,611,613

LCE3C/B

0

rs10888503

1

152,593,549

HLA-C

0

rs1050414

6

31,239,506

HLA-C

0

rs12189871

6

31,251,924

HLA-C

0

rs13214872

6

31,255,008

HLA-C

0

rs13210419

6

31,266,977

TNFAIP3

0

rs9321623

6

137,958,265

PsV ctl

PsA ctl

PsC ctl

PsA PsC

X
X
X
X

X

X
X
X

RAFe

PsC versus Controlf

Meta-OR

Meta-OR

Meta-p

PsA-ctl versus PsC-ctlg

Meta-p
8

A/C

0.3487

1.024

0.53

1.223

2.2 3 10

T/G

0.2525

1.296

2.5 3 1012

1.084

0.023

A/G

0.3368

1.319

7.8 3 1014

1.162

1.6 3 105

T/C
X

X

Allelesd

PsA versus Controlf

0.6413

1.085

0.018

1.8 3 10

11

4.020

6.5 3 10

225

1.247
70

OR

p

0.837

2.0 3 104

1.196

1.8 3 104

1.135

0.0075

0.870

0.0014

0.580

1.7 3 1021

G/C

0.1150

2.333

1.5 3 10

T/C

0.1429

2.631

5.6 3 1086

4.462

6.6 3 10248

0.590

2.2 3 1019

G/C

0.5621

2.416

2.3 3 1099

3.231

1.2 3 10206

0.748

5.5 3 109

A/G

0.0929

2.778

1.8 3 1084

5.004

3.5 3 10249

0.555

5.7 3 1021

C/T

0.5461

1.201

5.9 3 108

1.025

0.44

1.172

2.2 3 104
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Abbreviations are as follows: Chr, chromosome; RAF, risk allele frequency; PsV, psoriasis vulgaris; PsA, psoriatic arthritis; PsC, cutaneous psoriasis; ctl, control; OR, odds ratio.
a
Round of stepwise conditional association analysis: 0, unconditional analysis; 1, first round stepwise conditional; 2, second round stepwise conditional, etc.
b
For insertions or deletions of the hg19 human reference sequence, position of first base before the insertion point or of first base of the deleted sequence is shown, respectively.
c
An X indicates, for each of the four analyzed phenotype comparisons (PsV case versus control subjects, PsA case versus control subjects, PsC case versus control subjects, PsA case versus PsC case subjects), that the marker is
either the most strongly associated variant in the region with a p % 1 3 107 (unconditional meta-analysis) or the best associated independent locus with a p % 1 3 106 at the specified round of the stepwise conditional
meta-analysis.
d
Risk and nonrisk alleles based on results of association analysis of PsV case subjects and unaffected control subjects.
e
Risk allele frequency for unaffected controls.
f
For regions with a single independently associated variant, OR and p value are for a fixed-effects meta-analysis of PsA or PsC case versus unaffected control subjects where no other loci are included as conditioning covariates;
for regions with multiple independently associated variants, OR and p value are for fixed-effects meta-analysis where the logistic regression model includes the other independent risk variants in the region as conditioning
covariates.
g
OR and nominal p value for a bootstrap test of the equality of the log(OR)s from meta-analyses of PsA versus control and PsC versus control subjects for the six study discovery sample; p values % 0.05 after FDR adjustment are
indicated in the final column.

Figure 2. Comparison of PsC and PsA Associations for the TNFRSF9 and LCE3C/B Regions
Negative log10-transformed p values from meta-analyses of association for the six discovery datasets are shown for 800-kb regions encompassing genes TNFRSF9 (AC) and LCE3C and LCE3B (DF). For each region the SNP with the most significant association for the
comparison of PsC case subjects with unaffected control subjects is labeled. The color of each symbol denotes the strength of LD (r2 coefficient) with the index SNP. (A) and (D) Shown are association results for PsA case versus control subjects (A, D), for PsC case versus
control subjects (B, E), and for a conservative parametric test of the difference in log(OR) values from the PsA versus control and PsC
versus control subjects (C, F) comparisons. The bottom two panels give the physical positions of known genes in each region.

Functional Annotation
We investigated potential functional consequences of
associated variants for eight regions where this study
has enhanced our knowledge of the genetics of psoriasis
and PsA: CDKAL1 (PsV variant), TNFRSF9 and LCE3C/B

(PsC-specific association), IL23R and TNFAIP3 (PsA-specific associations independent of known PsV variants),
and IFIH1, IL12B, and NOS2 (secondary PsV, PsC, and
PsA signals independent of previously reported risk
variants).

826 The American Journal of Human Genetics 97, 816–836, December 3, 2015

Figure 3. Comparison of PsA and PsC Associations for the IL23R and TNFAIP3 Regions
Negative log10-transformed p values from meta-analyses of association for the six discovery datasets are shown for 800-kb regions
encompassing genes IL23R (AC) and TNFAIP3 (DF). For each region two reference SNPs are labeled—the red and blue diamonds
denote the variant that was most significantly associated for a test of PsA case versus control subjects or PsC case versus control
subjects, respectively. For all other plotted variants, the color and shape of the symbol denotes which index SNP the variant is
in highest LD with (red circles for the PsA index, blue triangles for the PsC index), and the intensity of the color indicates the
magnitude of the pairwise LD r2 coefficient. Shown are association results for PsA case versus control subjects (A, D) and for PsC
case versus control subjects (B, E). Results for a conservative parametric test of the difference in log(OR) values from the PsA versus
control and PsC versus control comparisons shown in (C) and (F). The bottom two panels give the physical positions of known
genes in each region.

Dendrograms for LD-based hierarchical clustering
(Figure S17) show that 7 of the 22 associated variants detected by this study in these regions were not in strong
LD (r2 R 0.7) with published variants for any genetic trait.

These include the primary PsV signal near TNFRSF9, one of
the secondary IL23R PsV signals, the primary PsV and secondary PsA signals in the IFIH1 region, the primary PsV,
PsA, and PsC as well as one of the secondary PsV signals
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Figure 4. Liability Plots for Five Regions
with Multiple Independent Psoriasis
Variants
Liability plots for five genomic regions—
near IL23R (A), IFIH1 (B), IL12B (C),
TNFAIP3 (D), and NOS2 (E)—with multiple
independent variants associated with psoriasis or its cutaneous and joint subphenotypes. Percent variance in disease liability
explained by each variant was computed
and adjusted for LD dependencies with
other variants in the region by the method
of Ho et al.69 The label above each plotted
symbol indicates both the associated
phenotype (P ¼ PsV, A ¼ PsA, C ¼ PsC)
and the round of conditional association
analysis (0 ¼ unconditional, 1 ¼ first round
conditional, 2 ¼ second round conditional, etc.). Grey fill for a plotted symbol
indicates that the association ORs for the
variant in the six-study meta-analysis of
PsA case versus unaffected control subjects
and PsC case versus unaffected control subjects were not significantly different; red
fill indicates a significantly larger OR for
the PsA versus control comparison. LD
blocks, shown with two alternating shades
of green, were delineated by the D0 confidence interval method68 using genotypes
for all SNPs with MAF R 0.05 in the 379 individuals of European ancestry in phase 1
of the 1000 Genomes Project.65 The bands
for the r2 clumps, shown in two shades of
purple when necessary, encompass clusters
of markers with an average pairwise r2 LD
coefficient R 0.3.

near IL12B, and the secondary PsV signal near NOS2. Of
the remaining 15 risk variants, all but the CDKAL1 SNP
and the PsA-specific signal upstream of TNFAIP3 were in
strong LD with previously reported variants for PsV or
PsA; other diseases sharing these variants or variants in
strong LD with them include Crohn disease (MIM:
266600), ulcerative colitis (MIM: 266600), inflammatory
bowel disease (MIM: 266600), ankylosing spondylitis
(MIM: 106300), multiple sclerosis (MIM: 126200), type 1
diabetes (MIM: 222100), selective IgA deficiency (MIM:
137100), systemic lupus erythematosus (MIM: 152700),
and vitiligo (MIM: 606579). All of these immune-mediated
diseases have been reported to share susceptibility signals
with psoriasis.27,87,88
Overlap of association signals with various functional
features is presented in Table S15. Because the most significantly associated variants are not necessarily causative,
for each signal we computed a Bayesian credible set that
had a 95% posterior probability (PP) of including the
causal disease-associated variant.72,73 To accommodate
uncertainty about which variant drives an association
signal, we annotated by computing weighted averages of

each feature over all variants in the
credible set, using PPs as weights.
Most of the association signals in
the eight regions were intronic or intergenic. Only the
two independent PsA association signals in IFIH1 had a
PP > 0.50 of being exonic; the index variants for these signals are missense SNPs with a high likelihood (PP ¼ 0.79
and 0.97) of being causal. Another variant likely to influence protein expression is a 32-kb indel spanning LCE3C
and LCE3B, which is in complete LD with the index SNP
for this region and is known to be associated with psoriasis.85,89 Many of the association signals fell within regions
bearing evidence of regulatory function. The strongest
such evidence was for the PsA-specific signal near IL23R,
which was in a region with promoter histone marks,
enhancer histone marks, and DNase I hypersensitive sites
for a weighted average of 40, 11, and 12 different cell
types, respectively, among 127 reference epigenomes.
The evidence for the index variant of this signal,
rs12044149, was even more striking: 67, 15, and 19 cell
types, respectively, where the SNP was located within
chromatin having promoter histone marks, enhancer histone marks, and DNase I hypersensitive sites; location
within a CpG island; and a 2b (‘‘likely to affect binding’’)
RegulomeDB score. Another association signal with
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multiple lines of evidence for regulatory function was the
likely causative SNP for the best PsV and PsC association
with NOS2 (rs28998802), which alters binding motifs for
seven transcription factors (TFs), is scored as likely to
affect TF binding, and contains DNase I hypersensitive
sites in 11 cell types.
Figure S18 shows overlap of association signals in the
eight regions of interest with chromatin states for 33
cell types relevant to psoriasis and PsA. As before, the
PsA-specific signal near IL23R appears to be located within
an important regulatory region, showing promoter-proximal activity in many relevant cell types, including monocytes, neutrophils, mononuclear cells, most T helper cells,
CD8þ T cells, fibroblasts, keratinocytes, melanocytes,
mesenchymal stem cell-derived cells, and osteoblasts.
The strongest secondary IL12B signal for PsV and PsA
(P1/A1) shows enhancer activity in NK cells, in all three
keratinocyte cell lines and in T regulatory cells, and also
in activated T helper cells. The primary PsV signal for
IFIH1, which is intronic, is in a region of transcriptional
activity for most cell types, but exhibits enhancer activity
in memory T helper and T regulatory cells. In contrast,
both NOS2 signals are located in regions that are silenced
by Polycomb group proteins in the majority of relevant
cell types.
Regulatory mechanisms often affect RNA expression.
Accordingly, we examined differential expression in psoriasis lesions versus skin from unaffected individuals for
all genes within 500 kb of the index signal in each of
the eight regions of interest, as well as evidence that the
associated regions contain cis-eQTLs for any of these
genes (Table S16). Most of the plausible candidate genes
in these eight regions showed a substantial (fold-change
[FC] > 2 or < 0.5) and significant (p < 1 3 106) difference in RNA expression between lesional and normal
skin. Expression of the inflammation-related genes
IFIH1, IL12B, IL23R, NOS2, and TNFRSF9 was higher in lesional compared to normal skin (FC ¼ 2.8, N, 4.4, 50, and
6.0, respectively). TNFAIP3 was the only inflammationrelated candidate gene showing no sign of differential
expression. The gene-dense LCE3C/B region teems with
plausible candidate genes; most (25/37) were dramatically
up- or downregulated in psoriatic skin. After correction
for multiple testing, only the PsV signal in the LCE3C/B
region provided evidence for being an eQTL in skin tissue. The risk alleles for all 27 variants in the 95% Bayesian
credible set for this locus showed a highly significant
negative correlation with mRNA levels of both LCE3C
and LCE3B (p % 1 3 1024 and p % 2 3 1012, respectively), and the peak eQTL variant for each gene
(rs67488802 and rs10888503, respectively) was in the
credible set. However, the risk alleles of the associated variants are all in very strong LD (r2 R 0.98) with a 32-kb
deletion spanning LCE3C and LCE3B and hence are simply markers for the absence of these two genes. The
associated variants in this region also showed a significant (p ¼ 1.4 3 105) positive correlation with LCE3A

expression, but the peak eQTL for LCE3A (rs138035792,
p ¼ 1.6 3 106) is not in the 95% Bayesian credible set
for the association signal.

Discussion
This study is a well-powered and comprehensive examination of the genetic associations of PsA and PsC. We found
five independent variants that are differentially associated
with these two subphenotypes, all in regions of known association with psoriasis.
A signal in the class I MHC between HLA-C and HLA-B
exhibited by far the greatest degree of differential association in our analysis, with carriage of the PsV risk allele
nearly halving the odds of developing PsA in addition to
PsC. Previous work using the same six discovery samples
of this study demonstrated that this differential association is driven by a glutamine residue at position 45 of
HLA-B, which increased PsA versus PsC susceptibility
more than any other classical HLA protein allele, amino
acid, SNP, or indel in the region.44 This amino acid is situated in the antigen binding groove of HLA-B, with potential influence on receptor cell-surface expression or antigen
peptide binding or presentation.44,90
The PsA-specific association near IL23R was previously
reported by us91 and has been recently confirmed.45 The
index variant in both studies is the same (rs12044149),
increasing the likelihood that this SNP is causal. However,
although the confirmatory study demonstrated that this
association is independent of previously reported psoriasis
associations, our study demonstrates that the SNP itself is
significantly more strongly associated with PsA than PsC.
SNP rs12044149 lies in a region with promoter-proximal
activity in diverse cell types, including many relevant to
psoriasis (Table S15, Figure S18). We found no evidence
that this SNP is a cis-eQTL for IL23R mRNA levels in skin
tissue, but IL23R-expressing immunocytes likely to be of
relevance to PsA (including IL17A-expressing CD4þ and
CD8þ T cells92) are relatively minor components of normal
and psoriatic skin.93 This SNP is only 32 bp from the
transcription start site (TSS) of uncharacterized proteincoding gene C1orf141 (versus 31.5 kb from the TSS of
IL23R), and its risk allele also shows a nominally significant
(p ¼ 0.0036) positive correlation with IL12RB2 (MIM:
601642) mRNA levels in skin tissue, suggesting that its
risk effect might be mediated via regulation of genes in
this region other than IL23R. Our results also support the
existence of at least three independent effects at the
IL23R locus for psoriatic disease (Table S11, Figures 4
and S17).
We also discovered a PsA-specific variant (rs9321623) in
the TNFAIP3 region, which is LD independent of the best
PsV and PsC associations. This SNP is one of a spatial
cluster of seven (rs9321623, rs7769192, rs13192841,
rs2327832, rs10499194, rs17264332, and rs6920220) associated with a variety of immune-mediated diseases, which
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spans a 48-kb interval that is intergenic and situated more
than 180 kb upstream of the TSS of TNFAIP3. However,
only one of the risk variants for these other diseases
(rs7769192, a secondary signal for multiple sclerosis94) is
allied with the PsA variant (LD-r2 ¼ 0.85). When aggregated over all variants in the 95% Bayesian credible set,
there is no compelling evidence that this PsA association
signal lies in a regulatory region (Table S15, Figure S18).
The index variant does, however, fall within an enhancer
element in many cell types relevant to psoriasis and PsA,
including CD14þ monocytes, mesenchymal stem cells, fibroblasts, keratinocytes, and osteoblasts (data not shown).
However, TNFAIP3 is not differentially expressed in
normal versus psoriatic skin, and the PsA-specific signal
shows no evidence of being an eQTL for TNFAIP3 in
skin-derived transcriptomes (Table S16).
We established that a known psoriasis signal within a
cluster of 19 LCE genes in the epidermal differentiation
complex on chromosome 1q21.322,23,27 is more strongly
associated with PsC than PsA. Published evidence for
association of PsA with variants in the LCE region is
mixed,95–99 but a meta-analysis of 2,400 PsA case and
7,779 control subjects from five European countries
found a nominally significant association (OR ¼ 1.14,
p ¼ 0.00041).95 We also found a nominally significant
association of PsA with PsV index variant rs10888503
(OR ¼ 1.085, p ¼ 0.021), but the association with PsC
was far stronger (OR ¼ 1.247, p ¼ 1.8 3 1011). The index
SNP is in perfect LD with a 32 kb deletion spanning LCE3C
and LCE3B that has been shown to be associated with
psoriasis to a degree equal to or better than any SNP surrogate.85,89 We found a highly significant positive correlation between copy number and mRNA levels of LCE3C
and LCE3B in skin tissue (Table S16). Expression of these
two genes was strongly upregulated in psoriasis lesions
compared to normal skin (72.8- and 12.5-fold increase,
respectively), and they encode late cornified envelope
structural proteins thought to be involved in skin barrier
repair after injury or inflammation.100 It has been theorized that lower levels of these LCE3 proteins due to the
deletion impairs response of the skin barrier to exogenous
agents, thereby facilitating the systemic skin inflammation
characteristic of psoriasis.101 It has also been demonstrated
that the 32 kb indel possesses epidermal-specific developmental in vivo enhancer activity,102 which might also
play a role in the association with disease.
The final differential association we detected is tagged
by SNP rs4908742, which lies between ERRFI1 (MIM:
608069) and SLC45A1 (MIM: 605763) on chromosome
1p36.23. This association signal appears to be specific to
PsC (OR ¼ 1.223, p ¼ 2.2 3 108), with no detectable association to PsA (OR ¼ 1.028, p ¼ 0.53). Although this region
contains susceptibility variants for several other autoimmune diseases, none of them are in LD with rs4908742
or the published27 psoriasis variant (Figure S17). There
are at least four plausible candidate genes in this region
(TNFRSF9, ERRFI1, SLC45A1, and RERE [MIM: 605226]),27

all of which are differentially expressed in both normal
and psoriatic skin, especially TNFRS9, which is 6-fold upregulated, and SLC45A1, which is 2.4-fold downregulated in
psoriasis lesions. The 95% Bayesian credible set for this locus contains 59 variants, and the PP for the index variant is
only 0.091. Thus, further refinement of this PsC association signal is needed before the target or mechanism of action of the risk variant in this region can be determined.
Other than a nominally significant greater association
with PsC than PsA for a known PsV variant within
IL23R21 and a recently published PsA signal in PTPN22,48
we could not confirm any of the prior reports of differential
association of these two subphenotypes with non-MHC
genetic variants (Table S13) even though this study had
greater power and used a more stringent definition of
PsC than most prior reports.
Given the marked distinction in phenotype, heritability,
and incidence of PsA and PsC, it is remarkable that we can
detect or confirm only five differentially associated signals,
all within known regions of PsV association. Much of this
might stem from the fact that this study, though based on
a large sample, is still underpowered compared to recently
published case-control studies of PsV and other genetic
traits.103 The consequences of this disparity in power are
also reflected by this study when comparing its greater
effective sample size for PsV-control versus PsA-control
and PsC-control comparisons (22,128 versus 10,604 and
9,996) with the resulting number of independent risk variants identified (40 versus 20 and 19, respectively) and the
total percent of variance in phenotypic liability explained
(14.4% versus 9.2% and 12.1%, respectively). Another limitation of this study is that two of the six discovery studies
had targeted rather than GW coverage, which biases discovery to loci already implicated in psoriasis and other
autoimmune diseases. It is likely that larger GWASs of
PsA and PsC will uncover more variants specific to each
subphenotype, aided by enhanced imputation resources
such as the Haplotype Reference Consortium.
In addition to uncovering differential associations with
PsA and PsC, we discovered GW significant association
with PsA for three regions (near IFNLR1, IFIH1, and
NFKBIA) and with PsC for five regions (TNFRSF9, LCE3C/B,
TRAF3IP2, IL23A, and NFKBIA). This increases the list of
firmly established PsA and PsC risk regions to 16 and 12,
respectively.
We also substantiated a PsV susceptibility signal within
the 50 portion of the 700 kb CDKAL1 gene. Nominal association of psoriasis to a SNP in this region has been noted
previously.104,105 The index SNP for this signal (rs4712528)
is in strong LD with a risk variant for Crohn disease, but it
is completely LD independent of a susceptibility variant
for inflammatory bowel disease and a host of SNPs that increase risk for type 2 diabetes (MIM: 125853) and an array
of other metabolic traits (Figure S17). CDKAL1 was expressed at significantly lower levels in psoriatic lesions
than in normal skin (FC ¼ 0.77, p ¼ 3.7 3 1014), in keeping with an observation that CDKAL1 transcription is
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downregulated when immune cells expressing the gene
(especially CD4þ, CD8þ, and CD19þ lymphocytes) are
activated.105 We found no evidence that this signal is an
eQTL for CDKAL1 or that it maps to a regulatory feature,
but the relatively low PP of the index variant (0.22) and
the long interval spanned by the 95% Bayesian credible
set (568 kb) indicate that deciphering the role of this locus
in psoriasis will depend upon better refinement of the association signal.
Only 2 of 17 previously unreported associations were
replicated, including only one of three signals achieving
GW significance in the discovery analysis (Table 2). After
adjusting discovery results for the well-known winner’s
curse67 and correction for multiple testing, none of the
17 markers showed a significant difference between
the ascertainment-adjusted OR of the discovery set and
the observed OR of the replication set. Post hoc power tests
indicated that only for rs4891505 in LOC100505817 was
there high confidence that power to replicate exceeds
80%, although the predicted power for the successfully
replicated CAMK2G variant was respectable (43%). These
results show that although effect sizes in the discovery
and replication sets are similar for the candidate variants,
the replication set is underpowered to replicate most of
the true positives among them. Power to replicate NFKBIZ
was also reduced by the need to substitute the second-best
associated marker for the index variant (compare p for
these two variants in Table S10). The PsA versus PsC signal
in LOC100505817 is probably a false positive, given its
much reduced significance when including the PsA
GWAS in the discovery analysis and its poor showing in
the replication set.
Conditional association analysis revealed multiple independent risk variants in regions of known psoriasis association, several of which have not been reported previously
(Table S11, Figures 4 and S17). Besides signals near IL23R
and TNFAIP3 that have already been discussed, we detected multiple variants for IFIH1, NOS2, and IL12B. Three
independent associations were found for the IFIH1 region—a PsV signal tagged by rs17715343 in this study
and rs17716942 in previous studies;23,27 a signal associated
with both PsA (rs1990760) and PsV (rs211485) that also
poses risk for type 1 diabetes, vitiligo, systemic lupus erythematosus, ulcerative colitis, and irritable bowel
syndrome; and a PsA signal at rs3747517. The PsA signals
at rs1990760 and rs3747517 are only 4.7 kb apart, but
their risk alleles usually occur on different haplotypes
(r ¼ 0.73). The IL12B region harbors at least five independent risk variants for psoriatic disease. One cluster contains most of the previously reported associations for PsV
and PsA (rs4921482, rs2546890, rs4379175, rs3213094,
rs2082412,
rs7709212,
rs6887695,
rs3212227,
rs228831),18,21,22,25,27,29,45,72 along with the strongest secondary PsV and PsA (rs62377586) and PsC (rs4921485)
signals from this study, as well as risk SNPs for multiple
sclerosis (rs2546890) and Crohn disease (rs6556412).
A second group includes a secondary PsV, PsA, and PsC

signal from this study, rs12188300, which is known to be
associated with PsA33 and PsV.27 Three additional clusters
contain variants not previously implicated in psoriasis susceptibility: a group with the best signal for PsV, PsA, and
PsC (rs918520), a secondary PsV signal (rs6870256), and
a group containing secondary PsV signal rs953861, secondary PsA signal rs1592975, plus SNPs associated with
ankylosing spondylitis and Crohn disease. The NOS2
region contains three independent psoriasis associations—rs28998802, the best PsV and PsC signal of this
study as well in a large meta-analysis of PsV;27 a known
PsV signal tagged by rs4795067;24 and rs2301369, a newly
implicated secondary PsV signal.
Data mining suggests plausible functional consequences
for some of the variants in the eight regions where this
study has added to our knowledge of genetic susceptibility
to psoriasis and its subphenotypes. These include variants
that might mediate their risk via protein alterations
(PsV-associated deletion of LCE3B and LCE3C and two independent PsA-associated missense SNPs in IFIH1), promoter-proximal regulation (PsA-specific IL23R SNP),
enhancer-mediated regulation (PsV signal in IFIH1, strongest secondary PsV and PsA signal in IL12B region), and
reversal of Polycomb repression (two independent NOS2
variants). Given the great cost and labor involved in experimental follow-up studies, it is crucial to identify the causative variants driving the observed associations. This will
require larger samples of affected case subjects that are
densely genotyped or deeply sequenced for the entire
genome. Correlation of the resulting finely mapped genetic information with transcriptomes and epigenomes
of relevant cell types will aid prediction and therapy of psoriasis and its cutaneous and joint manifestations.
Accession Numbers
Genotypes for the PsA GWAS have been deposited in dbGaP under
accession number phs000982.v1.p1.

Supplemental Data
Supplemental Data include 18 figures and 16 tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2015.10.019.
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33. Hüffmeier, U., Uebe, S., Ekici, A.B., Bowes, J., Giardina, E., Korendowych, E., Juneblad, K., Apel, M., McManus, R., Ho, P.,
et al. (2010). Common variants at TRAF3IP2 are associated
with susceptibility to psoriatic arthritis and psoriasis. Nat.
Genet. 42, 996–999.
34. Ellinghaus, E., Stuart, P.E., Ellinghaus, D., Nair, R.P., Debrus,
S., Raelson, J.V., Belouchi, M., Tejasvi, T., Li, Y., Tsoi, L.C.,
et al. (2012). Genome-wide meta-analysis of psoriatic
arthritis identifies susceptibility locus at REL. J. Invest. Dermatol. 132, 1133–1140.
35. Gonzalez, S., Martinez-Borra, J., Torre-Alonso, J.C., GonzalezRoces, S., Sanchez del Rı́o, J., Rodriguez Pérez, A., Brautbar,
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51. Höhler, T., Grossmann, S., Stradmann-Bellinghausen, B., Kaluza, W., Reuss, E., de Vlam, K., Veys, E., and Märker-Hermann, E. (2002). Differential association of polymorphisms
in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann. Rheum. Dis. 61, 213–218.
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